Results 201 to 210 of about 126,669 (262)

Development of angiotensin II type 1 receptor antibodies in patients with temporary mechanical circulatory support. [PDF]

JHLT Open
Gamero MT, Liotta M, Brailovsky Y, Gibson G, Alvarez R, Uber P, Huang Y, Rajapreyar I.   +7 more
europepmc   +1 more source

Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress [PDF]

, 2011
XY Tian, Wing Tak Wong, Aimin Xu, Zhen‐Yu Chen, Ye Lu, Liu Lm, Vivian Lee, CW Lau, Xiaoqiang Yao, Yü Huang   +9 more
openalex   +1 more source

Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper

ESC Heart Failure, EarlyView.
The graphical abstract summarizes the key features of AFMR in terms of epidemiology, pathophysiology, diagnosis, medical therapy and rhythm control, surgical and transcatheter interventions, and future directions. Created in BioRender (https://BioRender.com/3zj03ko).
Matteo Pagnesi, Mauro Riccardi, Francesco Maisano, Julia Grapsa, Vassilis Barberis, Magdy Abdelhamid, Elena‐Laura Antohi, Henrike Arfsten, Nicole Karam, Denisa Muraru, Karl‐Philipp Rommel, Anna Sannino, Wilfried Mullens, Marianna Adamo, Marco Metra   +14 more
wiley   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

ESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori, Sergio Davinelli, Armando Ferrera, Alessandro Medoro, Carlo Barsali, Allegra Battistoni, Maurizio Volterrani, Massimo Volpe, Luciano Saso, Speranza Rubattu   +9 more
wiley   +1 more source

Activation Induces Structural Changes in the Liganded Angiotensin II Type 1 Receptor [PDF]

, 2009
Martin Clément, Jérôme Cabana, Brian J. Holleran, Richard Leduc, Gaétan Guillemette, Pierre Lavigne, Emanuel Escher   +6 more
openalex   +1 more source

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

ESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage, Jason N. Dungu, Anthony Dimarco, Brian Li, Samantha Langley, Jonathan Kojo Amoah, Paraic Cliffe, Archana Ganapathy, Peter Watters, Patricia Campbell, Nicola Melarkey, Simon Duckett, Sean Davies, Matthew Dewhurst, Karen Hann, Louise Clayton, Rhys Williams, Victoria Ruszala, Teresa Onwere‐Tan, Fozia Zahir Ahmed, Ibrahim Arosi, Kimberly Gray, Mark C. Petrie, John G.F. Cleland   +23 more
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source

Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.

JAMA, 2023
Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine N, Tiffany B, Douglas IS, Levitt J, Busse LW, Ginde AA, Brown SM, Hager DN, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall AJ, DeClercq J, Lavieri R, Joly MM, Orr M, Pulley J, Rice TW, Schildcrout JS, Semler MW, Wang L, Bernard GR, Collins SP, ACTIV-4 Host Tissue Investigators.   +46 more
europepmc   +1 more source

Pathogenic glycosyltransferase genes and potential therapeutic drugs in pressure overload‐induced heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Protein glycosylation regulated by glycosyltransferases is an important type of post‐translational modification. The role of the glycosyltransferase genes (GTGs) in heart failure (HF) remains unclear and requires further investigation.
Jiahe Wu, Yi Lu, Xinchen Gao, Xiaorong Hu, Zhibing Lu, Chenze Li   +5 more
wiley   +1 more source